



NEUROBIOLOGICAL TECHNOLOGIES (NTII)

The FDA has granted the firm's investigational drug, **Viprinex™** (ancrod), fast-track status for use in patients suffering from **ischemic stroke**. The drug is under development for decreasing disability in patients with **acute non-hemorrhagic stroke** within six hours of symptoms. The advantage of this drug, if approved would be the fact that it can be administered up till six hours after the stroke – three hours more than what the only available drug offers. The three hours significantly limits the number of patients that can be treated. It is estimated that less than five percent of stroke patients are suitable for current therapies to date and less than three percent actually receive treatment. **The estimated direct and indirect costs of stroke in the U.S. in 2004 are thought to be \$53.6 billion.**

Viprinex (ancrod) was previously studied in approximately 2,000 patients in various clinical studies in the U.S. and Europe.

Neurobiological Technologies acquires and develops central nervous system related drug candidates. The company is focused on therapies for neurological conditions that occur in connection with dementia, Alzheimer's disease, ischemic stroke, neuropathic pain, and brain cancer. The stock is trading at around **\$3.80**.

RESONNANCE HEALTH (ASX: RHT)

This firm's subsidiary, **Inner Vision Biometrics Pty Ltd (IVB)**, has achieved FDA marketing approval for **FerriScan™** its novel non-invasive diagnostic test for liver iron concentration. FDA 510(k) approval **allows IVB to market the FerriScan™** test in the United States where an estimated four million people are afflicted with an iron overload disease such as haemochromatosis and thalassaemia. The FerriScan™ test provides a **safe alternative to liver biopsy and will become a valuable adjunct to gene testing for iron overload diseases. Liver biopsy is an unpleasant, invasive procedure requiring liver tissue to be extracted from the patient by needle**

FDA 510(k) approval for FerriScan(TM) follows the listing of FerriScan™ by the Australian regulatory authority, the Therapeutic Goods Administration (TGA), and European CE Mark approval achieved at the end of 2004. FerriScan™ can now be marketed in the two largest international markets, the USA and Europe. Existing partnerships with leading diagnostic imaging companies will be used to offer the FerriScan™ test to the public in Australia and Europe. Partnerships with diagnostic imaging companies are also being developed for the USA.

The U.S. FDA marketing approval, the achievement of European CE Mark and listing on the ARTG by the TGA in Australia will enable access to the major international markets for the FerriScan test. We plan to partner with leading diagnostic imaging companies in the US, Europe and Australia to offer the FerriScan™ test to the public

Haemochromatosis and Thalassaemia: Haemochromatosis is a genetic disorder that causes iron deposition in the liver and in other organs of the body, resulting in iron overload. The condition frequently remains undiagnosed because of lack of awareness, its long latency period and its non-specific symptoms. **Thalassaemia**, a genetic blood disorder and a very severe and debilitating form of anaemia, also results in iron overload due to the requirement for frequent blood transfusions.

Resonance Health Limited controls 51% of the voting rights of Inner Vision Biometrics Pty Ltd (IVB) and is earning 51% of the equity of IVB via the progressive injection of further capital. FerriScan(TM) is 100% owned by IVB.

FerriScan™ is a novel, non-invasive diagnostic test of the iron content of a patient's liver to assist clinicians in the detection and treatment of iron overload disorders such as thalassemia and hereditary haemochromatosis.

THE
F
PHENOMENON

When biotech firms finance (most have to), the market's rule of thumb that general traders and investors blindly follow is to sell the stocks. Here are some possibilities in today's market. This phenomenon has only a temporary effect.

TELIK (TELK): The stock could be **negatively affected** by the **F Phenomenon**, the rule of thumb investors follow by **selling stocks of firms that finance, especially through public offerings**. Telik announced the pricing of its public offering of 7,000,000 shares of its common stock at **\$18.75** per share. The **offering was increased by 2,000,000** shares over the proposed offering announced on January 24, 2005.

Telik, Inc. of Palo Alto, CA is a biopharmaceutical company working to discover, develop and commercialize innovative small molecule drugs to treat diseases. The company's most advanced drug development candidates are for the treatment of cancer.

La JOLLA PHARMACEUTICAL (US LGPC): The firm also announced that it intends to offer 12,250,000 shares of its common stock in a public offering. Stock Last trade \$1.44

Prohost R.

**P.O.Box 640429
Oakland Gardens, N.Y. New York, 11364
Tel: 516 678 1335
Fax: 718 423 2731
E-mail: Prohost@aol.com**

FORWARD LOOKING STATEMENT: Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at: <http://www.sec.gov/consumer/cyberfr.htm>